Navigation Links
Cepheid Highlights Promising Early Performance Of Its Cervical Cancer Test At AMP
Date:11/14/2013

SUNNYVALE, Calif., Nov. 14, 2013 /PRNewswire/ -- At its Corporate Workshop at the Association of Molecular Pathology (AMP) meeting in Phoenix yesterday, Cepheid shared early performance data for its test for cervical cancer-related human papillomaviruses, Xpert® HPV, which is currently in clinical trials with a targeted CE-IVD release in early 2014. 

"We're pleased with the early Xpert HPV data that highlight Cepheid's commitment to delivering tests that offer the unmatched combination of performance, ease-of-use and speed that our customers expect of the Xpert brand," said John Bishop, Cepheid's Chairman and Chief Executive Officer.  "This test is a another important milestone in the extension of the Xpert test menu available outside the United States, which extends meaningfully in 2014 to include not just HPV, but HIV and HCV, in addition to a number of other products."

"Highlighting Cepheid's history of innovation, the GeneXpert® System defined – and delivers today - the 'sample-in, answer-out' molecular testing solution that defines the essential capability for broad market dissemination that many others are aspiring to bring to market," continued Bishop.  "Our GeneXpert System now has an installed base of more than 5,000 systems in 139 countries, with a menu of 14 available Xpert tests spanning Healthcare Associated Infections, Critical Infectious Disease and Sexual Health.  Looking forward, Cepheid's focus is on further extension of our installed base and Xpert test menu, and of course, to further enhancements in our GeneXpert System to ensure we are able to maintain our market leadership in the years ahead."

Xpert HPV is a multiplexed test that targets the E6/E7 region of 14 cancer-related HPV types and specifically calls out types 16 and 18/45 in separate detection channels, with 11 other high-risk types detected in combined channels.

"Consistent with our expectations, the clinical trial data to date suggest that Xpert HPV performs as well as the market leading assays, but in a format that is unprecedented in its ease of use and time-to-result," said David Persing, M.D., PhD, Cepheid's Chief Medical and Technology Officer.  "The test incorporates several new design features that we believe position it well for medical practice dynamics of the future given the potential growing importance of HPV type 45 in clinical diagnosis."

The Company's presentation, given by Philip Castle, Ph.D., MPH, Executive Director of the Global Cancer Initiative and Executive Director of the Global Coalition Against Cervical Cancer, is available for download at www.cepheid.com.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated testing solutions for infectious diseases, oncology, and genetic conditions by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

CONTACTS:


For Media Inquiries:

For Investor Inquiries:

Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

communications@cepheid.com

Jacquie Ross, CFA

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com

 


'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cepheid Launches Mobile Community for Ride Against TB Campaign to Benefit the American Lung Association
2. Cepheid Receives FDA Market Authorization for Xpert MTB/RIF
3. Cepheid and American Lung Association Partner for Tuberculosis Awareness in U.S.
4. Cepheid Schedules 2013 First Quarter Results Announcement And Webcast
5. Cepheid Reports Fourth Quarter And Full Year 2012 Results
6. Cepheid Announces Executive Vice President Emerging Markets
7. Cepheid to Webcast Upcoming Financial Presentations
8. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
9. Soligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
10. Isis Reports Financial Results and Highlights for Third Quarter 2013
11. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):